EnGen Bio is an innovative brand at the forefront of scientific research and discovery. With a focus on combating Type A influenza, their team of dedicated scientists has made a groundbreaking breakthrough. They have developed an isolated monoclonal antibody capable of targeting and neutralizing all four significant sequence variants of the exposed M1 region, known as the epitope.

This means that just one antibody specificity can recognize and combat all Type A viruses, including pandemic influenzas. Building on this exciting finding, EnGen Bio has developed a new type of universal therapy and vaccine for Type A viruses. Through extensive in vitro and animal testing, they have confirmed the efficacy of their approach.

Their engineered peptide immunogen, when used as a vaccine, induces an immune response in animals and confers protection from viral challenges. EnGen Bio's groundbreaking discovery lies in targeting the surface-exposed M1 epitope, utilizing the immune system's response to provide comprehensive protection against Type A influenza. With further optimization, they are on a path to creating a universal Type A influenza vaccine that could revolutionize global health